CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Shanghai, China –August 6, 2025 – Everest Medicines (HKEX 1952,“Everest”, or the Company), a biopharmaceutical company focused on the discovery, cl ...

Purespring Therapeutics has secured approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002.

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

KDPMA elects Jatish N Sheth as president for the term 2025 to 2027: Our Bureau, Bengaluru Wednesday, August 6, 2025, 15:45 Hrs [IST] Karnataka Drugs and Pharmaceuticals Manufactur ...

US FDA clears Hemispherian’s IND application for first-in-class glioblastoma therapeutic, GLIX1: Oslo, Norway Wednesday, August 6, 2025, 15:00 Hrs [IST] Hemispherian AS, a pione ...

To better detect cardiovascular diseases in people, researchers used high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) to simultaneously quantify metabolites in human plasma ...

Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- <p ...

DelveInsight’s, “ Idiopathic Pulmonary Fibrosis Pipeline Insights 2025 ” report provides comprehensive insights about 80+ ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

The regulator is allowing the firm to submit data on 4D-150 from a single Phase III trial and draw on readouts from previously conducted studies in wet AMD.